Amphastar Pharmaceuticals Inc logo

AMPH - Amphastar Pharmaceuticals Inc Share Price

$20.08 0.0  0.0%

Last Trade - 17/01/20

Sector
Healthcare
Size
Mid Cap
Market Cap £720.8m
Enterprise Value £713.9m
Revenue £251.3m
Position in Universe 2505th / 6416
Bullish
Bearish
Unlock AMPH Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AMPH Revenue Unlock AMPH Revenue

Net Income

AMPH Net Income Unlock AMPH Revenue

Normalised EPS

AMPH Normalised EPS Unlock AMPH Revenue

PE Ratio Range

AMPH PE Ratio Range Unlock AMPH Revenue

Dividend Yield Range

AMPH Dividend Yield Range Unlock AMPH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AMPH EPS Forecasts Unlock AMPH Revenue
Profile Summary

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated May 19, 2004
Public Since June 25, 2014
No. of Shareholders: 170
No. of Employees: 2,078
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite , S&P 600 Small Cap , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 46,938,027
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AMPH Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AMPH
Upcoming Events for AMPH
Similar to AMPH
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.